is director of the Comprehensive Epilepsy Center and co-director of the Genetic Pharmacology Service. His research has focused on improving the care of children with epilepsy through identifying the genetic and non-heritable factors that underlie the inter-individual variation in response to antiepileptic medications. Since 2003, he has directed the NIH-funded Childhood Absence Epilepsy trial, a 31-center, 446-patient double-blind randomized comparative trial of three commonly used antiepileptic medications focused on identifying the optimal initial therapy for children with childhood absence epilepsy and the pharmacokinetic, pharmacodynamic, and pharmacogenetic factors that impact the inter-individual response to antiepileptic therapy. Glauser and the Genetic Pharmacology Service
have also developed and are testing treatment selection algorithms for epilepsy and non-epilepsy medications that incorporate genetic information and drug-drug interactions.